{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:12:05Z","timestamp":1791223925910,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Sunovion Pharmaceuticals Inc., Marlborough, MA and Fort Lee, NJ"}],"content-domain":{"domain":["jad-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.jad.2013.10.040","type":"journal-article","created":{"date-parts":[[2013,10,28]],"date-time":"2013-10-28T13:15:18Z","timestamp":1382966118000},"page":"20-27","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"special_numbering":"C","title":["Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed"],"prefix":"10.1016","volume":"155","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6098-9266","authenticated-orcid":false,"given":"Leslie","family":"Citrome","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence A.","family":"Ketter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine","family":"Cucchiaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7591-8647","authenticated-orcid":false,"given":"Antony","family":"Loebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2013.10.040_bib1","unstructured":"AstraZeneca, 2011a. Seroquel (quetiapine fumarate). Revised December 2011. Available from: \u3008http:\/\/www1.astrazeneca-us.com\/pi\/Seroquel.pdf\u3009 accessed 28.01.13."},{"key":"10.1016\/j.jad.2013.10.040_bib2","unstructured":"AstraZeneca, 2011b. Seroquel XR (quetiapine fumarate extended release). Revised December 2011. Available from: \u3008http:\/\/www1.astrazeneca-us.com\/pi\/seroquelxr.pdf\u3009 accessed 28.01.13."},{"key":"10.1016\/j.jad.2013.10.040_bib3","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1176\/appi.ajp.162.7.1351","article-title":"A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression","volume":"162","author":"Calabrese","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2013.10.040_bib4","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1600-0447.2008.01194.x","article-title":"Compelling or irrelevant? Using number needed to treat can help decide","volume":"117","author":"Citrome","year":"2008","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.jad.2013.10.040_bib5","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1586\/14737175.8.7.1079","article-title":"Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks","volume":"8","author":"Citrome","year":"2008","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.jad.2013.10.040_bib6","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2174\/157488609789006985","article-title":"Quantifying risk: the role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications","volume":"4","author":"Citrome","year":"2009","journal-title":"Curr. Drug Saf."},{"key":"10.1016\/j.jad.2013.10.040_bib7","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1600-0447.2009.01449.x","article-title":"Relative vs. absolute measures of benefit and risk: what is the difference?","volume":"121","author":"Citrome","year":"2010","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.jad.2013.10.040_bib8","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1517\/14656566.2011.632368","article-title":"Olanzapine\u2013fluoxetine combination for the treatment of bipolar depression","volume":"12","author":"Citrome","year":"2011","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.jad.2013.10.040_bib9","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1742-1241.2010.02587.x","article-title":"Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic","volume":"65","author":"Citrome","year":"2011","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.jad.2013.10.040_bib10","doi-asserted-by":"crossref","first-page":"412","DOI":"10.4088\/JCP.11ac06874","article-title":"Number needed to treat: what it is and what it is not, and why every clinician should know how to calculate it","volume":"72","author":"Citrome","year":"2011","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2013.10.040_bib11","doi-asserted-by":"crossref","first-page":"455","DOI":"10.2165\/11589060-000000000-00000","article-title":"Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder","volume":"31","author":"Citrome","year":"2011","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.jad.2013.10.040_bib12","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3371\/CSRP.6.2.5","article-title":"Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?","volume":"6","author":"Citrome","year":"2012","journal-title":"Clin. Schizophr. Relat. Psychoses"},{"key":"10.1016\/j.jad.2013.10.040_bib13","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/ijcp.12142","article-title":"When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed","volume":"67","author":"Citrome","year":"2013","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.jad.2013.10.040_bib14","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jad.2013.06.027","article-title":"Placing transdermal selegiline for major depressive disorder into clinical context: number needed to treat, number needed to harm, and likelihood to be helped or harmed","volume":"151","author":"Citrome","year":"2013","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2013.10.040_bib15","unstructured":"Eli Lilly, 2013. Symbyax (olanzapine and fluoxetine hydrochloride). Revised January 2013. Available from: \u3008http:\/\/pi.lilly.com\/us\/symbyax-pi.pdf\u3009 accessed 28.01.13."},{"key":"10.1016\/j.jad.2013.10.040_bib16","series-title":"Handbook of Diagnosis and Treatment of Bipolar Disorder","author":"Ketter","year":"2010"},{"key":"10.1016\/j.jad.2013.10.040_bib17","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1600-0447.2010.01645.x","article-title":"Treatments for bipolar disorder: can number needed to treat\/harm help inform clinical decisions?","volume":"123","author":"Ketter","year":"2011","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.jad.2013.10.040_bib19","article-title":"Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study","author":"Loebel","year":"2013","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2013.10.040_bib20","article-title":"Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study","author":"Loebel","year":"2013","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2013.10.040_bib21","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1097\/JCP.0b013e31825ccde5","article-title":"Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome?","volume":"32","author":"Lombardo","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2013.10.040_bib27","doi-asserted-by":"crossref","first-page":"156","DOI":"10.4088\/JCP.09r05385gre","article-title":"Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis","volume":"72","author":"Sidor","year":"2011","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2013.10.040_bib22","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1177\/016327870202500206","article-title":"Individualizing treatment decisions. The likelihood of being helped or harmed","volume":"25","author":"Straus","year":"2002","journal-title":"Eval. Health Prof."},{"key":"10.1016\/j.jad.2013.10.040_bib23","unstructured":"Sunovion, 2013. Latuda (lurasidone). Revised July 2013. Available from: \u3008http:\/\/www.latuda.com\/LatudaPrescribingInformation.pdf\u3009 accessed 07.08.13."},{"key":"10.1016\/j.jad.2013.10.040_bib24","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jad.2009.10.007","article-title":"Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression","volume":"121","author":"Suppes","year":"2010","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2013.10.040_bib25","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/01.jcp.0000248603.76231.b7","article-title":"Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study)","volume":"26","author":"Thase","year":"2006","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2013.10.040_bib26","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archpsyc.60.11.1079","article-title":"Efficacy of olanzapine and olanzapine\u2013fluoxetine combination in the treatment of bipolar I depression","volume":"60","author":"Tohen","year":"2003","journal-title":"Arch. Gen. Psychiatry"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032713007829?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032713007829?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,11]],"date-time":"2018-10-11T04:52:43Z","timestamp":1539233563000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032713007829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":26,"alternative-id":["S0165032713007829"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2013.10.040","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2013.10.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}